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Abstract
Background: Parkinson’s disease (PD) disrupts temporal processing, but the neuronal sources of deficits and their response
to dopamine (DA) therapy are not understood. Though the striatum and DA transmission are thought to be essential for
timekeeping, potential working memory (WM) and executive problems could also disrupt timing.
Methodology/Findings: The present study addressed these issues by testing controls and PD volunteers ‘on’ and ‘off’ DA
therapy as they underwent fMRI while performing a time-perception task. To distinguish systems associated with
abnormalities in temporal and non-temporal processes, we separated brain activity during encoding and decision-making
phases of a trial. Whereas both phases involved timekeeping, the encoding and decision phases emphasized WM and
executive processes, respectively. The methods enabled exploration of both the amplitude and temporal dynamics of
neural activity. First, we found that time-perception deficits were associated with striatal, cortical, and cerebellar
dysfunction. Unlike studies of timed movement, our results could not be attributed to traditional roles of the striatum and
cerebellum in movement. Second, for the first time we identified temporal and non-temporal sources of impaired time
perception. Striatal dysfunction was found during both phases consistent with its role in timekeeping. Activation was also
abnormal in a WM network (middle-frontal and parietal cortex, lateral cerebellum) during encoding and a network that
modulates executive and memory functions (parahippocampus, posterior cingulate) during decision making. Third,
hypoactivation typified neuronal dysfunction in PD, but was sometimes characterized by abnormal temporal dynamics (e.g.,
lagged, prolonged) that were not due to longer response times. Finally, DA therapy did not alleviate timing deficits.
Conclusions/Significance: Our findings indicate that impaired timing in PD arises from nigrostriatal and mesocortical
dysfunction in systems that mediate temporal and non-temporal control-processes. However, time perception impairments
were not improved by DA treatment, likely due to inadequate restoration of neuronal activity and perhaps corticostriatal
effective-connectivity.
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Introduction
Timing is a process that helps structure perception, cognition
and movement. Prevailing models emphasize the role of the
striatum and dopamine (DA) neurotransmission [1,2] in regulating
an internal clock that generates pulses and an accumulator that
counts pulses, thereby representing perceived duration. The
experience of time, however, can be dilated or compressed by
working memory (WM), attention, and decisional processes [3],
which are cortically driven. Thus, timing emerges from interac-
tions among multiple processes that are intertwined. When timing
is disentangled from other processes, the striatum is closely linked
to timing, whereas the supplementary motor area (SMA) and the
middle-frontal and inferior parietal cortices are more associated
with WM and executive processes, respectively [4].
The basal ganglia’s role in timing is particularly relevant to
individuals with Parkinson’s disease (PD), who exhibit temporal
processing deficits [5–12]. Timing deficits may contribute to the
breakdown in the spatiotemporal patterning of movements in
PD, which benefit from external rhythmic sensory-cueing [13].
The neuronal sources of timing impairments in PD and their
response to DA therapy are not well understood. Whether DA
therapy improves timing deficits is controversial [9–12,14–16].
To date, three fMRI and one PET study of timing have been
conducted in PD [16–19]. Only two of these studies examined
the effect of DA treatment [16,19], and all studied timed
movements, so that it was not possible to distinguish abnormal
activation in systems classically associated with motor-control
(i.e., basal ganglia, cerebellum) from activity related to temporal
processing.
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e17461The present study addressed these issues by testing PD participants
‘on’ and ‘off’ their DA therapy as they underwent fMRI while
performing a time-perception task. In this task, a standard interval
(SI) and a comparison interval (CI) were successively encoded,
followed by a decision about their relative duration. To identify
neural systems related to different components of temporal
processing, we separated brain activation associated with encoding
the SI and holding it inWM from activation associated with encoding
the CI and making a decision. We reasoned that the encoding phase
would emphasize timekeeping, but also WM maintenance. Whereas
the decision phase engages timekeeping as well, executive processes
involved in updating WM and comparing information is also
emphasized during this period [4,20,21]. We predicted that
abnormal basal ganglia activation in PD would be seen during both
phases if the striatum is critical for timekeeping. As SMA dysfunction
is common in PD, we also expected abnormal activation during both
phases if the SMA plays a key role in timekeeping [22]. Finally, we
predicted abnormal middle-frontal cortex activation during the
decision, but not the encoding phase if executive difficulties [23,24]
contribute to timing deficits in PD. To determine if the cognitive-
control systems emphasized by the two phases respond differently to
DA therapy [25], we studied the effects of medication on brain
activation and on striatal interactions with the cortex and cerebellum
(i.e., effective connectivity). Though DA therapy was expected to
improve striatal function, its effects on key cortical regions that
support time perception (e.g., SMA, middle-frontal and inferior-
parietal cortex) are unclear as this has not been previously studied.
Methods
Participants and Procedures
Participants included 21 volunteers with idiopathic PD (14
males, 7 females) and 19 healthy adults (12 males, 7 females). Age
and education were balanced between the groups (Table 1).
Subjects were excluded if they had metal in their body, exhibited
signs of dementia on a global dementia screening battery (Mini-
Mental Status Exam score ,25) and on neuropsychological tests of
cognitive speed/flexibility, working memory span, and sustained
attention (i.e., $1.5 standard deviations (SD) below the control
group; Table 1), exhibited signs of depression (Geriatric Depression
Score $10), or had a medical history of neurological diagnoses
other than PD, severe psychiatric disorders (DSM-IV), diabetes,
and alcohol or substance abuse. PD volunteers were excluded if
they had axial tremors or dyskinesias that could cause head
movement during scanning, or if they were taking cholinesterase
inhibitors or neuroleptic medications. ANOVAs showed no group
differences on neuropsychological tests of global dementia,
cognitive speed/flexibility, verbal and spatial working memory,
sustained attention and maximum tapping speed (Table 1).
Board-certified neurologists with a specialty in motor disorders
assessed all PD participants (D.D. Song and S. Lessig). PD
participants exhibited at least two of the three cardinal features of
the disorder (i.e., bradykinesia, resting tremor, motor rigidity),
were levodopa responsive, and did not exhibit features of
progressive supranuclear palsy, corticobasal degeneration, multi-
ple systems atrophy, or dementia. Eighteen PD participants were
taking levodopa/carbidopa, and all were taking one or more DA
agonists or releasers. The mean levodopa equivalence (LDE) was
748.3 (SD = 428) [26]. Symptoms on the motor examination
section of the United Parkinson’s Disease Rating Scale (UPDRS)
were worse off [Mean (SD) = 29.6 (10.4)] than on medication
[Mean (SD) = 22.2 (8.0)] [F(1, 20)=20.9, p,.0001, g
2=.51]. On
the Hoehn and Yahr, 18 and 3 PD participants were stage 2 and 3,
respectively, both off and on medication.
PD participants completed two fMRI sessions that were
conducted on separate days at the same time of day. For one
fMRI session, PD volunteers took their normal daily medication
dosage one hour before scanning (ON condition) so that they
were studied in an optimally medicated state. In the other fMRI
session, participants refrained from taking medication for at least
2 half-lives of the longest acting medication or a minimum of 16
to 24 hours before the scan (OFF condition) so that they were
studied in a ‘practical’ off state. The control subjects performed
the fMRI task once in the scanner and once in the laboratory;
only behavioral data from the scanning session were analyzed.
For both groups, the order of testing conditions was counterbal-
anced. The study was approved by the University of California,
San Diego (UCSD) Human Research Protections Program
(HRPP). Study participants signed written informed-consent
forms.
Functional MRI
fMRI task. In the time perception task (Figure 1A), subjects
attended to the duration of successively presented pairs of filled-
Table 1. Demographics, neuropsychological test
performance
1, and structural MRI volumes for the Control
and Parkinson’s groups.
Variables
Control
(n=19)
Parkinson’s
(n=21)
MS D M S D P
Demographics
Age 64.6 8.5 67.0 9.4 0.40
Education 17.1 2.7 15.9 2.8 0.20
Mini-Mental State Exam
2 28.6 1.1 28.7 1.6 0.87
Cognitive Speed/Flexibility
3
Trails A 48.4 9.9 46.1 7.5 0.33
Trials B 53.1 10.8 48.3 7.5 0.08
Working Memory Span
4
Digits Forward/Backward 13.2 2.4 12.4 3.5 0.10
Spatial Span Forward 11.1 3.3 9.5 2.4 0.10
Spatial Span Backward 14.2 2.3 13.2 2.5 0.20
Sustained Attention
5
Digit Vigilance Test 49.9 9.7 52.1 11.8 0.57
Motor Speed
6
Finger Tapping (right hand) 50.0 8.4 45.0 10.2 0.41
Structural MRI volumes
7
Bilateral putamen, GP 0.9 0.1 0.9 0.1 0.90
Bilateral caudate 0.5 0.1 0.5 0.1 0.10
Total Cortical Gray 28.1 1.4 27.0 2.6 0.09
Total Cerebellar Gray 6.2 0.8 6.3 0.8 0.78
1Neuropsychological testing was conducted in PD participants when they were
taking their medication.
2The total score (maximum = 30) is reported for the Mini-Mental State Exam
[57].
3T-scores are reported for the Trail Making Test [58].
4Scaled scores are reported for the Digit Span and Spatial Span tests [59].
5T-scores are reported for the Digit Vigilance Test [60].
6T-scores for the dominant right hand are reported for the Finger Tapping Test
[58].
7Volumes are expressed as the percentage of estimated total intracranial
volume (volume/eTIV).
doi:10.1371/journal.pone.0017461.t001
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stimulus was shorter or longer than the first. Throughout the
experiment, the subject maintained fixation on a white cross at the
center of the display. One second before trial onset, a warning
signal (i.e., flashing yellow cross and mixed 700-Hz tone) appeared
for 500 ms followed by a 500 ms delay. Trial onset began with
presentation of an auditory (1000 Hz pure tone) or visual (blue
circle) SI that lasted 1200 or 1800 ms, and was respectively
followed by a 6800 or 6200 ms delay. Then a CI of the same
modality was presented, after which the subject indicated if it was
shorter or longer than the SI by pressing a key with the right index
or middle finger. For each SI, there were 3 shorter and 3 longer
CIs that differed from the SI by successive increments of 67%.
Two SIs were used to help ensure that subjects encoded signal
duration on each trial. The analyses collapsed across SI duration.
The analyses also collapsed across signal modality, as there were
no group differences in timing auditory and visual signals (see
Results section), consistent with other reports [7]. Accuracy and
reaction time (RT; from offset of the CI to key press) were
measured. We did not include a sensorimotor control task since
processing in sensory areas was of interest to our study.
There were 30 trials per SI condition (i.e., auditory 1200 ms,
auditory 1800 ms, visual 1200 ms, and visual 1800 ms), with 5
trials per CI for a total of 120 trials. Trials were divided into 8 runs
of 15 trials each. Within a run, SI conditions were randomly
presented. Image acquisition was synchronized with the onset of
the SI and the CI. Each trial included a minimum of 9 images (i.e.,
18 s) to reduce the likelihood of nonlinear summing of overlapping
hemodynamic responses. Additional one to five ‘filler’ 2.0 s epochs
(fixation cross) were randomly added to the end of each trail (i.e.,
45 filler images per run). Jitter in the inter-trial interval allowed for
the best sampling of the hemodynamic response and establishment
of a baseline resting state in the model (i.e., fixation plus ambient
scanner noise). A run began and ended with 5 additional filler
images to respectively allow for T1 equilibration and the delayed
hemodynamic response of the final trial. Each run consisted of 190
images acquired over 6 min and 20 s.
Image acquisition. Imaging was conducted at the UCSD
Center for FMRI using a GE 3-T Excite MRI system equipped
with an 8-channel head-coil. Whole-brain blood-oxygen level
dependent (BOLD) weighted echo-planar images were acquired
using a single-shot, blipped, gradient-echo echo-planar pulse
Figure 1. Time perception paradigm and task performance. A) Trial events for the auditory and visual conditions of the time perception task.
Trials were preceded by a 500 ms warning signal (i.e., flashing yellow fixation cross and a mixed 700 Hz auditory tone). At trial onset, an auditory or
visual standard-interval (SI) (1200 or 1800 ms) was presented and followed by a delay (6800 or 6200 ms). At 8 s post-trial onset, a comparison interval
(CI) of the same modality was presented. Image acquisition (TR = 2 s) was pegged to the onsets on the SI and CI. The first 12 s of a trial (i.e.,
equivalent to 6 TRs) constituted the encoding phase. The last 12 s of a trial constituted the decision phase. B) Mean (standard error bars) accuracy for
the auditory (left) and visual (right) conditions in the control group and PD OFF and ON conditions. Accuracy data were converted to the mean
percent longer, and averaged across the two SI conditions and their respective CIs. On the x axis, 67, 14, and 21 designate CIs that were 7%, 14%, and
21% shorter (negative values) or longer (positive values) than the SI.
doi:10.1371/journal.pone.0017461.g001
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resolution = 64664). Thirty-seven contiguous, axial 4-mm slices
(3.7563.7564-mm voxel size) provided whole-brain coverage.
High-resolution T1-weighted anatomic images were collected for
anatomic localization (3D spoiled gradient-recalled at steady-state,
TE=3.0 ms, TR=7.8 ms, 12u flip angle, number of excitations
(NEX) = 1, 1-mm slice thickness, FOV=25 cm, resolution =
2566256). Foam padding was used to limit head motion. Auditory
stimuli were delivered binaurally through a headphone that
together with earplugs attenuated background scanner noise by
about 40 db. Visual stimuli were viewed through a mirror
mounted on the head-coil.
Image analysis. Functional images were generated using
Analysis of Functional NeuroImages (AFNI) software. Time series
images were spatially registered in 3-dimensional space and
corrected for time-slice acquisition differences. A deconvolution
analysis (correcting for scanner drift) was used to generate impulse
response functions (IRFs) of the fMRI signal on a voxelwise basis.
Each IRF was estimated relative to the baseline state (i.e., filler
images), without a priori assumptions about the shape, delay, or
magnitude of the IRF. Six head-motion parameters were included
as covariates of no interest. Estimates of percent signal change
(PSC) for each image acquired 0 s to 24 s post-stimulus onset were
then calculated by taking the beta coefficient and dividing it by the
model intercept. The PSC maps were interpolated to volumes with
1-mm
3 voxels, co-registered, converted to Talairach coordinate-
space, and blurred using a 4-mm Gaussian root mean square filter.
Spatial extent analysis. This analysis examined the within-
group spatial extent of activation. For each group (control, PD
ON, PD OFF), statistical parametric maps were generated to
identify voxels that exhibited a significant change in activation (i.e.,
PSC estimates) during each phase of the trial. Figure 1A shows
that the first 12 s of a trial (i.e., 6 TRs) constituted the encoding
phase, during which the subject encoded the SI and held it in
memory; the last 12 s constituted the decision phase, wherein the
subject encoded the CI and judged its duration relative to the SI.
Repeated-measures ANOVAs for each group tested the effect of
time (i.e., 6 TRs for each phase), separately for the encoding and
decision phases of a trial. Voxelwise thresholds were derived from
3,000 Monte Carlo simulations (AFNI AlphaSim), which
computed the voxel probability and minimum cluster-size
threshold needed to obtain a .05 familywise alpha. Because
spatial thresholds are biased against smaller activation clusters of a
priori interest (i.e., basal ganglia and midbrain nuclei), statistical
thresholds were derived separately for basal ganglia/midbrain and
cortical volumes [27]. This was accomplished by creating a basal
ganglia/midbrain mask (i.e., claustrum, putamen, globus pallidus
(GP), caudate, substantia nigra (SN), red nucleus, and subthalamic
nucleus) using the Talairach Daemon dataset; the mask was then
expanded to include any voxels within a 2 mm radius. The cortical
mask included all other regions of the brain including the
cerebellum. Each mask was used in the Monte Carlo simulations
to determine the appropriate combination of individual voxel-
probability and minimum cluster-size threshold. For the basal
ganglia/midbrain volume, a voxelwise threshold of p,.008 and a
minimum cluster size of .225 ml yielded a .05 familywise alpha.
For the cortical volume, a voxelwise threshold of p,.004 and a
minimum cluster size of .338 ml yielded a .05 familywise alpha.
Functional region of interest analysis. A functional region
of interest (fROI) analysis was conducted to evaluate potential
group differences. A fROI map was generated by conjoining
activated regions identified in the above spatial extent analyses
across the control group and the PD ON and OFF conditions.
Thus, any voxel significantly activated in at least one of the groups
or conditions contributed to the final fROI map. Two conjunctive
maps were generated, one for the encoding and one for the
decision phase. Masks from the Talairach Daemon dataset were
then used to separate large clusters into functionally relevant
regions, which were the basis for all subsequent analyses.
Rather than focusing exclusively on peak activation, we
analyzed group differences in the temporal dynamics or evolution
of brain activity, since this might better characterize neuronal
functioning as it does in normal aging [28]. This approach also
avoided problems with assuming equivalence among regions in the
time delay of hemodynamic responses to an event [29]. We first
compared fROI between the control group and the OFF condition
to evaluate the effects of disease on activation. The 2 (group; G) X
6 (time; T, where Tencoding phase = the first 6 TRs and Tdecision phase
= the last 6 TRs of a trial) mixed-model ANOVA tested for the
main effect of group (G) and its interaction with time (G X T),
separately for the encoding and the decision phases. Next,
regions that showed significant group effects were compared
between the OFF and ON conditions to evaluate medication
effects. The 2 (medication condition; Med) X 6 (T) repeated-
measures ANOVA tested the main effect of medication con-
dition (Med) and its interaction with time (Med X T), separately
for the encoding and decision phases. If medication had an
effect, mixed-model ANOVAs compared the ON condition with
the control group to determine if DA normalized activation. The
significance threshold was set at p,.03 for the cortical volumes
and at p,.05 for the basal ganglia/midbrain volumes as the
latter involved far fewer comparisons. The Huynh-Feldt correc-
tion adjusted for heterogeneity of variance in multiple degrees-
of-freedom tests.
Effective connectivity analysis. In addition to the univariate
teststhat assessed the effectof medication on activation of individual
fROI, we also asked if DA therapy altered interactions of the
striatum with the cortex and cerebellum. This was achieved by
conducting voxel-based tests of psychophysiological interactions
(PPI) separately forthe encodinganddecision phases[30]. Voxels in
the bilateral caudate and putamen, which showed abnormal
activation OFF medication, were the seed ROI and were selected
for each subject using the conjunctive maps generated for the fROI
analyses. The experimental variable was medication state (ON,
OFF). Multiplication of the deconvolved time series for the seed
areas with the experimental variable formed the interaction term
(i.e., PPI regressor), which tested whether connectivity of the
striatum with the whole brain was modulated by medication. A
p,.005 voxelwise threshold and a .225 ml minimum cluster size
was the criterion for significance.
Structural MRI Analysis
To assess group differences in striatal, cerebral, and cerebellar
volume, automated cortical reconstruction and volumetric seg-
mentation of T1-weighted images was performed using FreeSurfer
(http://surfer.nmr.mgh.harvard.edu/), which is a vertex-based
approach. Processing included removal of non-brain tissue using a
hybrid watershed/surface deformation procedure [31] and trans-
formation to Talairach space. This was followed by segmentation
of subcortical white- and deep gray-matter volumetric structures
[32], intensity normalization [33], tessellation of the gray-white
matter boundary, automated topology correction [34,35], and
surface deformation following intensity gradients to optimally
place the gray/white and gray/cerebrospinal fluid borders at the
location where the greatest shift in intensity defines the transition
to the other tissue class [34]. Transformation and segmentations
were manually verified. This approach provides anatomically
accurate renderings of regional volumes, without potential rater
Temporal Processing in Parkinson’s
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divided by estimated total intracranial volume (eTIV). Table 1
shows that striatum and cerebral/cerebellar gray-matter volumes
did not differ between groups (p values ..05).
Results
fMRI Task Performance
Accuracy was converted to the percent longer responses for
each CI, per convention. CIs that were increments of 67%, 14%
or 21% shorter/longer than the SI were averaged across the SI
conditions. A mixed-model ANOVA compared the control group
with the OFF condition, testing the main effect of group, modality
(audition, vision), CI, and the interactions. The group X CI
interaction [F(3.6,137.6)=3.8, p,.005] was due to worse
performance (i.e., flatter slope, lower accuracy) in the OFF
condition than in the control group (Figure 1B). The modality X
CI interaction [F(5,190)=2.3, p,.05] indicated that performance
was worse for visual than auditory intervals in both groups. No
other significant effects were found. The OFF and ON conditions
were then compared. The repeated-measures ANOVA showed no
effect of medication on performance, irrespective of modality. This
was consistent with a mixed-model ANOVA comparing the
control group with the ON condition, which showed a group X CI
interaction [F(3.2,121)=3.4, p,.02]. No other group effects were
found. As for RTs, group and medication effects were not
significant (Mean (SE): Controls = 2316 ms (68); OFF =
2322 ms (65); ON = 2404 ms (74)). However, RTs were longer
for visual (Mean (SE) = 2390 ms (54)) than auditory intervals
(Mean (SE) = 2292 ms (54) in both groups [F1,38)=7.0, p,.01].
fMRI Spatial Extent Analysis
Descriptive analyses of the spatial extent of activation indicated
that total volume of activation was reduced in both phases by
approximately 28% in the PD OFF group relative to the controls.
Frontal, parietal, and temporal lobe volumes were reduced 15% to
20% in the OFF group, irrespective of phase. However, Figure 2
shows that for both phases volume reductions of more than 25%
Figure 2. Spatial extent of activation in areas showing reduced volumes in the PD OFF condition. Activation volumes for the left and
right hemispheres combined are displayed for the encoding and decision phases in the C (red bars), PD OFF (black bars) and PD ON (grey bars)
groups. Areas are displayed that showed reduced volumes of more than 25 percent in the PD OFF condition relative to the control (C) group. See
Figures S1 and S2 for activation volumes in the whole brain, and Tables S1 and S2 for details about activation foci.
doi:10.1371/journal.pone.0017461.g002
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cingulate (33% for both phases), thalamus (36% to 39%), striatum
(27% to 30%), midbrain nuclei (27% to 30%), parahippocampus
(83% to 85%), occipital lobe (39% to 49%), and cerebellum (65%
for both phases). Whereas medication appeared to increase
activation extent, Figure 2 shows that the spatial extent of
activation typically remained lower relative to the control group
(see Figures S1 and S2 for activation volumes in the whole brain,
and Tables S1 and S2 for details about activation foci).
Functional ROI Analysis
The conjoined fMRI activation-masks in Figure 3 show that
similar regions of activation were found during both phases of the
trial (see Table S3 for details about activation foci). Figure 3 also
shows that group differences were found in only a subset of these
regions (i.e., yellow), and were partially related to the behavioral
context. For example, the PD OFF group exhibited abnormal
preSMA/SMA/cingulate, precentral, middle-frontal, parietal,
insula, inferior-temporal, right-parahippocampus, and lateral-
cerebellum activation during the encoding phase. In contrast,
posterior-cingulate and left-parahippocampus activations were
abnormal during the decision phase. Only the striatum and
vermis exhibited abnormal activation during both phases. We
now turn to the statistical analyses in support of these
observations.
Encoding phase: PD OFF versus control. Table 2 lists
regions wherein activation during interval encoding differed
between the control and PD OFF groups, and Figure 4 displays
activation time-courses in representative regions for the first half of
the hemodynamic response (i.e., encoding period). This figure
shows that hemodynamic responses return to baseline in some
fROI, but not in others because the trial extends beyond the
encoding of the SI, including activity related to WM maintenance.
In all regions, the temporal dynamics of activation differed
between the groups (G X T). In the striatum, hemodynamic
responses were attenuated and temporally lagged OFF medication
relative to controls. Hemodynamic responses were also attenuated
OFF medication and returned to baseline levels soon after peak
activation in left preSMA/SMA/cingulate, left precentral gyrus,
bilateral postcentral gyrus, left inferior-temporal cortex, and right
insula; by comparison, activation in the control group was robust
for longer periods. In contrast, right middle-frontal gyrus (MFG),
left inferior-parietal cortex, and bilateral lateral cerebellar activity
was attenuated OFF medication and prolonged relative to the
Figure 3. Functional ROI for the encoding (A) and decision phases (B). Functional ROIs were derived from conjoining activation maps in
Figures S1 and S2, respectively. Yellow regions designate significant group (Control vs. PD OFF) differences in activation; red regions indicate no
significant group differences. Brain activation is projected onto the lateral and medial surfaces of the left and right hemispheres (rows 1 and 2), the
anterior and posterior surfaces of the cerebellum (row 3), and the left and right basal ganglia (row 4). See Table S3 for details about individual fROI.
doi:10.1371/journal.pone.0017461.g003
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medication in the right parahippocampus and vermis.
Encoding phase: Medication. Table 2 and Figure 4 show
that medication altered activation in the right parahippocampus,
the right insula and the vermis (Med X T). In all three regions,
comparisons between the ON and the control groups indicated
that medication normalized activation.
Decision phase: PD OFF versus control. Table 3 and
Figure 5 show regions wherein the temporal dynamics of
activation during decision making differed between the controls
and the OFF condition (G X T). In bilateral putamen, peak
activation was normal, but prolonged relative to controls. In
bilateral caudate, peak activation was lagged, attenuated and
prolonged relative to controls. No significant activation was seen in
the posterior cingulate and the left parahippocampus, and there
was only a trend (p,.05) for vermis activation; these results
contrasted with significant activation in the control group in all
three regions. No other group differences were found.
Decision phase: Medication. Table 3 and Figure 5 show
that medication altered activation time-courses only in the bilateral
putamen and vermis. Medication significantly attenuated the
prolonged time-courses of putamen activity, but did not normalize
activation relativeto the control group (GX T: p,.025). In contrast,
medication enhanced and normalized vermis activity.
Effective Connectivity Analysis
Effective connectivity analyses showed that interactions of the
striatum withthecortexwere modulatedby DA therapy, butonly in
the decision phase. Table 4 and Figure 6 show that DA therapy
significantly modulated interactions between the striatum and the
cortex (i.e., SMA, precentral and postcentral gyrus, superior frontal
gyrus (SFG), MFG, superior and inferior parietal cortex, precuneus,
and insula), but not the cerebellum. Figure 7 graphs representative
PPI. Corticostriatal interactions were stronger OFF than ON
medication. An exception was stronger connectivity ON than OFF
therapy between the left putamen and the left SFG (BA 6).
Discussion
The present study uncovered four new findings that elucidated
neurobehavioral mechanisms of time perception deficits in PD and
their response to DA therapy. First, impaired time perception OFF
medication was associated with abnormal activation in systems
regularly associated with time perception in studies of healthy
adults [4,20,36–38] including the striatum, selected cortical sites
(e.g., preSMA/SMA, cingulate gyrus, precentral and postcentral
gyri, insula, middle-frontal and inferior-parietal cortex, parahip-
pocampus) and the cerebellum (lobules, vermis). Unlike studies of
timed movement, our results could not be attributed to classic
Table 2. Regions showing significant group and medication effects during the encoding phase.
Control vs PD OFF
1 PD OFF vs PD ON
2
Region BA X Y Z ml Group X Time Medication X Time
Frontal
[1] L preSMA/SMA, cingulate 6,24,31 28 27 45 24.1 .02
[2] L Precentral 4,6 243 27 37 17.5 .03
[3] R Middle 6,9,10,46 36 19 37 17.7 .01
Parietal
[4] L Postcentral 2,3 245 223 37 9.0 .005
[5] R Postcentral 3,5 56 218 22 3.5 .01
[6] L Inferior 40 246 241 37 19.0 .03
Temporal
[7] L Inferior 20 257 215 219 9.6 .025
[8] R parahippocampus 36 25 236 27 6.0 .03 .01
[9] R Insula (anterior & posterior) 13 40 28 9 12.0 .025 .02
Basal Ganglia
[10] L Putamen, GP 224 23 5 7.1 .01
[11] R Putamen, GP 25 24 5 6.7 .005
[12] L Caudate (body, tail) 220 213 15 4.5 .05
[13] R Caudate (body, tail) 21 216 16 3.5 .05
Cerebellum
[14] B Vermis 0 263 23 4.8 .006 .03
[15] L Lobule 4–6 219 256 216 2.5 .008
[16] L Lobule 7–10 221 260 234 20.8 .025
[17] R Lobule 7–10 23 259 234 19.3 .02
fROIs are displayed in Figure 3 (left column; yellow). Brodmann areas (BA) were defined by the Talairach and Tournoux atlas. Cerebellar lobules were defined by the
Schmahmann atlas [61]. Coordinates represent distance in mm from anterior commissure: x, right(+)/left (2); y, anterior (+)/posterior (2); z, superior (+)/inferior (2). B =
bilateral hemispheres; L= left hemisphere; R = right hemisphere; GP = globus pallidus; SMA = supplementary motor area.
1This column summarizes areas showing significant differences between the control and PD OFF groups in the temporal dynamics of activation during the first half of
the hemodynamic response (encoding period; G X T).
2This column summarizes areas showing significant differences between the ON and OFF medication conditions in the temporal dynamics of activation (Med X T).
doi:10.1371/journal.pone.0017461.t002
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PLoS ONE | www.plosone.org 7 February 2011 | Volume 6 | Issue 2 | e17461Figure 4. Percent signal change in regions showing abnormal activation OFF medication during the encoding phase. Graphs display
representative regions showing different time courses of activation between the control (red lines) and PD OFF (black lines) groups (G X T). The effect
of medication is also shown (PD ON; gray lines). The abscissa designates the time (sec) post-trial onset. The mean (standard error bars) percent signal
change (PSC) is graphed for the first half of the hemodynamic response (i.e., encoding period). Bracketed numbers reference regions detailed in
Table 2. B = bilateral hemispheres; L = left hemisphere; R = right hemisphere; SMA = supplementary motor area.
doi:10.1371/journal.pone.0017461.g004
Table 3. Regions showing significant group and medication effects during the decision phase.
Control vs. PD OFF
1 PD OFF vs. PD ON
2
Region BA X Y Z ml Group X Time Medication X Time
Parietal
[1] B Posterior cingulate 23 1 233 24 .5 .03
Temporal
[2] L parahippocampus 36 219 246 3 .5 .01
Basal Ganglia
[3] L Putamen, GP 223 22 3 9.8 .004 .03
[4] R Putamen, GP 24 22 5 7.8 .003 .03
[5] L Caudate (head, body, tail) 215 24 13 6.4 .025
[6] R Caudate (head, body, tail) 13 2 15 5.1 .003
Cerebellum
[7] B Vermis (anterior) 0 263 23 .6 .01 .05
fROIs are displayed in Figure 3 (right column; yellow). Brodmann areas (BA) were defined by the Talairach and Tournoux atlas. Coordinates represent distance in mm
from anterior commissure: x, right(+)/left (2); y, anterior (+)/posterior (2); z, superior (+)/inferior (2). B = bilateral hemispheres; L= left hemisphere; R = right
hemisphere; GP = globus pallidus.
1This column designates areas wherein the temporal dynamics of activation during the second half of the hemodynamic response (decision period) differed between
the control and PD OFF groups (G X T).
2This column designates areas wherein the temporal dynamics of activation differed between the OFF and ON medication conditions (Med X T).
doi:10.1371/journal.pone.0017461.t003
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Second, for the first time we were able to better distinguish
temporal and non-temporal sources of cognitive dysfunction in
time perception by separating activity during the encoding and
decision phases. Our finding of striatal dysfunction in both phases
was consistent with the role of DA neurotransmission in
timekeeping operations. In addition, our results suggested that
non-temporal operations emphasized by each phase were also
disrupted in PD. Specifically, activation was abnormal in a classic
WM network (middle frontal-inferior parietal, SMA, lateral
cerebellum) during the encoding phase, whereas activation was
absent in a network that mediates executive processes and memory
(posterior-cingulate, parahippocampus) during the decision phase.
Third, another novel finding was that neuronal dysfunction in PD
was sometimes characterized by abnormal temporal dynamics.
For example, hemodynamic responses of the striatum were
typically attenuated, but also temporally lagged and sometimes
prolonged; activity was also prolonged in a WM network (middle
frontal-inferior parietal cortex, lateral cerebellar). These findings
cannot be explained by longer RTs in PD, which did not differ
from the control group. Fourth, DA therapy did not alleviate time
perception deficits, despite its robust benefit on motor symptoms
(UPDRS). Our fMRI results suggested that this was likely due to
insufficient restoration of neuronal activation and perhaps
corticostriatal effective-connectivity. We now discuss these findings
more completely.
Striatal Dysfunction in PD
As predicted, striatal activation OFF medication was abnormal
during both phases of a trial, consistent with its role in
timekeeping. During interval encoding, attenuated and temporally
lagged striatal activity may suggest weakened and delayed
processing of input from multiple corticostriatal loops. Theoret-
ically, weakened and lagged striatal activation should disrupt
integration of cortical input over time, a key function of the ‘core
timer.’ Specifically, by the striatal beat frequency (SBF) model,
Figure 5. Percent signal change in regions showing abnormal activation OFF medication during the decision phase. Graphs display
regions showing different time courses of activation between the control (red lines) and PD OFF (black lines) groups (G X T) during the decision
phase. The effect of medication is also shown (PD ON; gray lines). The abscissa designates the time (sec) post-trial onset. The mean (standard error
bars) percent signal change (PSC) is graphed for the second half of the hemodynamic response (i.e., decision phase). Bracketed numbers reference
regions detailed in Table 3. B = bilateral hemispheres; L = left hemisphere; R = right hemisphere; GP = globus pallidus.
doi:10.1371/journal.pone.0017461.g005
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support the clock signal, and striatal medium-spiny neurons serve
as a core timer by detecting and integrating oscillatory states over
time [2]. Thus, impaired time perception in PD may be partially
related to deficient striatal integration of cortical input. This may
be due to diminished nigrostriatal phasic-DA, which it thought to
signal the onset and offset of a to-be-timed event [2].
We also found striatal dysfunction during the decision phase,
wherein peak activation of the putamen/GP was normal in PD,
yet sustained longer relative to the control group; caudate activity
was also sustained, but temporally lagged and attenuated.
Although both phases involve timekeeping, the duration of two
intervals is compared only during the decision phase. Sustained
striatal activity leads us to speculate that it reflects compensation
for difficulties in additional processes including updating WM with
the CI [39] and comparing it with the SI. These processes require
fast, flexible striatal-reactions, which are our study shows are
temporally lagged and sometimes prolonged in PD during decision
making and may be a basis for cognitive inflexibility [25].
Disease-Related Cortical and Cerebellar Activity
Time perception impairments OFF medication were also
associated with abnormal cortical and cerebellar activity. A
unique finding was that these abnormalities partially depended
on the context, despite activation of similar regions in both phases
(Figure 3 and Table S3 for details about activation foci for each
phase). During the encoding phase, hypoactivation was found in
the cerebellum (lobules, vermis) and cortical areas of the motor
(preSMA/SMA/cingulate, precentral/postcentral gyrus), execu-
tive (middle-frontal, inferior parietal), and limbic (parahippocam-
pus, insula, inferior temporal) corticostriatal loops [40]. In the
motor loop, preSMA/SMA dysfunction only during encoding was
notable as it is at odds with a fundamental role for the SMA in
timekeeping [22]. SMA dysfunction is common in PD and is
traditionally attributed to difficulties with internally-generated
behaviors. However, a more pivotal distinction may relate to its
role in WM, specifically online storage of output from the motor
pathway [4,41]. By this proposal, SMA dysfunction in PD should
be manifested particularly when maintenance is emphasized, as
during the encoding phase wherein the SI is held in memory for
over 6 s.
Memory-related difficulties during interval encoding were also
suggested by PD participants’ prolonged activation in a classic
WM-network (middle-frontal, precentral, inferior-parietal, lateral
cerebellum) [42]. This may suggest ‘compensatory processing’ for
diminished preSMA/SMA functioning, but perhaps also for
hypoactivity of the insular cortex, which has efferent connections
to WM networks and the striatum [43]. The insula integrates
processing from disparate domains (e.g., interoception, emotion,
WM) including time [4,36,37,44,45]. Recent models suggest that
Table 4. Cortical regions showing effective connectivity with the striatum that was modulated by medication.
Basal Ganglia Seed – Interacting Regions BA X Y Z ml
Left Putamen
[1] B SMA 6 2 219 55 1.0
[2] L Superior frontal
1 6 222 7 57 .2
[3] L Precentral gyrus 6 246 212 28 .2
[4] L Precentral, postcentral gyrus 3,4 223 232 62 .6
[5] L Precentral, postcentral, inferior parietal 3, 4, 40 237 224 45 2.3
[6] R Precentral, postcentral, superior parietal 3, 4, 7 29 236 56 2.0
[7] L Inferior parietal 40 247 230 25 .4
[8] B Precuneus 7 5 248 53 .3
[9] L Insula 13 249 226 19 .5
Right Putamen
[10] L Precentral gyrus 4 244 216 49 .2
[11] L Precentral, postcentral gyrus 3,4 222 234 64 .6
[12] R Precentral, postcentral gyrus 3, 4 31 228 56 .3
Left Caudate
[13] L Precentral, middle frontal 6 237 29 48 1.0
[14] L Precentral 4 235 221 37 .3
[15] L Precentral, postcentral gyrus 3,4 218 231 54 .4
[16] L Postcentral gyrus, inferior parietal 2, 3, 40 242 230 44 1.0
[17] L Inferior parietal 40 230 242 43 .7
Right Caudate
[18] L Middle frontal 6 234 264 1 . 3
[19] L Precentral, postcentral gyrus 3,4 221 232 57 .7
Regions showing effective connectivity each striatal seed are displayed in Figure 6. Brodmann areas were defined by the Talairach and Tournoux atlas. Coordinates
represent distance in mm from anterior commissure: x, right(+)/left (2); y, anterior (+)/posterior (2); z, superior (+)/inferior (2). B = bilateral hemispheres; L = left
hemisphere; R = right hemisphere; SMA = supramarginal gyrus.
1The correlation between a basal ganglia seed and a cortical region was typically greater OFF than ON medication. An exception was the correlation between the left
putamen and the left superior/middle frontal cortex (BA 6), which was greater ON than OFF medication.
doi:10.1371/journal.pone.0017461.t004
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PLoS ONE | www.plosone.org 10 February 2011 | Volume 6 | Issue 2 | e17461Figure 6. Cortical regions showing connectivity with the striatum that was modulated by medication. For each striatal seed region,
activation is projected onto the lateral and medial surfaces of the left and right hemispheres, which are displayed in neurological view. See Table 4 for
details about individual activation foci.
doi:10.1371/journal.pone.0017461.g006
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networks in generating accurate responses to salient or task-
relevant events [46,47]. In our study, insula dysfunction may be
manifested during interval encoding due to uncertainty about the
to-be-attended modality at trial onset, which accentuates atten-
tional demands. This prospect is compatible with normal insula
activation during the decision phase, wherein top-down attention
mechanisms might enhance insula activation since the CI modality
is certain as it always matches the SI. Memory-related deficits OFF
therapy were further evidenced in the encoding phase by the
striking absence of activity in the right parahippocampus, damage
to which disrupts time perception [48].
Cortical dysfunction during the decision phase was unexpect-
edly confined to a medial ‘default-mode network’ (left parahippo-
campus, bilateral posterior cingulate) [49]. Activation was absent
in this network OFF medication, in contrast to the control group.
To our knowledge, parahippocampus dysfunction has not been
reported in non-demented PD, whereas evidence for posterior-
cingulate dysfunction remains debated [50–52]. We speculate that
abnormal functioning of this network emerged during decision
making due to the emphasis on executive processes (e.g.,
comparison of the SI and CI) and/or retrieval, which are
modulated by this system [49]. Together with the absence of
activity in the right parahippocampus during the encoding phase,
deficient functioning of this network may underlie distortions in
memory for time in PD [9], and may be an early marker of
memory problems.
It was notable that vermis activity was greatly reduced OFF
medication during both phases, as was lateral cerebellar activity
during encoding. Our results contrast with cerebellar hyperactivity
in PD during timed movements [17–19], which is attributed to
compensation for striatal dysfunction. Although direct support for
this proposal is lacking, hyperactivity of the cerebellum during
timed movement, but not time perception may reflect an increased
reliance on sensorimotor-coordination functions of the cerebellum,
rather than purported timekeeping functions [53].
Dopamine Modulation of Brain Activation and
Corticostriatal Connectivity
Our results showed that DA therapy did not alleviate time
perception deficits, consistent with some [14], but not all studies
[9,11,12]. At first glance our results seem to conflict with the
effects of DA agonists and antagonists on timing in animals [1].
However, our fMRI findings suggest that time perception does not
benefit from DA therapy when activity is not sufficiently reinstated
in timekeeping and non-temporal control systems known to
mediate time perception. Specifically, during the encoding phase,
treatment did not alter activation in the striatum or a WM network
(SMA, middle frontal-inferior parietal cortex, lateral cerebellum),
nor did it affect interactions of the striatum with other brain areas
(effective connectivity). Likewise, during the decision phase
impoverished activity in the default mode network (posterior
cingulate, left parahippocampus) was not improved by DA
therapy, nor was activity in the caudate, which interacts with this
network [54].
There were some benefits of medication on brain activation, but
they were circumscribed. During the encoding phase, treatment
Figure 7. Scatter plots showing significant striatal-cortical connectivity that was modulated by medication. Scatter plots show the
relationship between striatal and cortical activity as a function of medication state in representative regions. Linear regression fits are overlaid on the
scatter plots. Gray squares and lines = PD OFF condition; black triangles and lines = PD On condition. Bracketed numbers refer to regions listed in
Table 4.
doi:10.1371/journal.pone.0017461.g007
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parahippocampus) and vermis activity, possibly via the mesocor-
tical-DA system. During the decision phase, DA therapy
normalized vermis activity and improved, but did not restore the
temporal dynamics of the putamen. Interestingly, DA therapy also
mediated striatal interactions with the cortex, but not the
cerebellum. Two patterns of effective connectivity were found,
consistent with a recent study of motor timing in PD [19]. First,
the striatum showed greater connectivity OFF than ON
medication with the MFG, SMA, precentral/postcentral cortex,
insula, and parietal cortex. Enhanced connectivity OFF therapy
might appear counterintuitive since corticostriatal connectivity can
be reduced OFF medication relative to controls [55]. However,
animal models suggest that enhanced connectivity after DA
depletion may reflect excessive synchronicity in corticostriatal
circuits [56], which disrupts rapid, flexible updating/integration
by the striatum in contexts that call for cognitive flexibility [25],
such as the decision phase. Second, we also found that the
putamen showed greater connectivity ON than OFF medication
with the left SFG. Enhanced connectivity ON medication could
reflect reduced inhibitory output from the striatum to an area that
normally supports temporal decision-making [4,20]. These
speculations require further research as mechanisms of effective-
connectivity in PD and their regulation by DA are not understood.
Altogether, our finding of DA-mediated striatal activation and
connectivity only during the decision phase is consistent with its
effects on flexibility control-mechanisms, which are driven by the
striatum and nigrostriatal DA [25]. Nevertheless, functioning is
not restored in networks important for time perception.
Summary
The present results illuminated the neurobehavioral mecha-
nisms of time perception deficits in PD by distinguishing abnormal
activity in the encoding and decision phases of a trial, which we
hypothesized would both engage timekeeping, but accentuate
demands on different non-temporal control processes. As predict-
ed, neuronal dysfunction was found in a purported timekeeping
center (striatum) in both phases. In addition, neuronal dysfunction
in the encoding and decision phases was respectively manifested in
WM/attentional (SMA, middle-frontal and inferior-parietal cor-
tex, lateral cerebellum, insula, right parahippocampus) and
executive processing/memory (left parahippocampus, bilateral
posterior cingulate) centers. The temporal dynamics of activation
in PD were also abnormal in the striatum and a frontoparietal-
cerebellar network, which better characterized the basis for
disturbances in timekeeping (temporally lagged and/or prolonged)
and WM (prolonged). However, DA therapy did not alleviate time
perception deficits in PD. Our fMRI results suggested that
restoration of neuronal functioning was insufficient, possibly due
to largely tonic effects of treatment, which fail to restore the
balance of phasic and tonic DA in nigrostriatal and mesocortical
pathways [8].
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